Hormones Dominate Sports Doping and Account for Two-Thirds of All Violations
A comprehensive review reveals androgens, EPO, and growth hormone remain the most potent and widely abused performance-enhancing agents in sport.
Summary
This chapter from Endotext provides a detailed overview of hormone-based doping in competitive sports. It explains how sports performance depends on four key components — skill, strength, endurance, and recovery — and how specific hormones are exploited to gain an edge in each. Androgens dominate doping violations, particularly in power and combat sports, by increasing muscle mass and strength. Blood doping via erythropoiesis-stimulating agents boosts endurance by enhancing oxygen delivery. Growth hormone and its secretagogues are used for recovery, though evidence for their ergogenic benefit is weak. Hormones account for roughly two-thirds of all anti-doping rule violations detected globally. The review also addresses glucocorticoids and thyroid hormones, noting that chronic use of both is likely counterproductive for athletic performance.
Detailed Summary
Hormone doping in sport is not merely a matter of fairness — it sits at the intersection of endocrinology, pharmacology, and public health. Understanding which hormones are abused, how they work, and how they are detected is essential for clinicians, sports medicine professionals, and anti-doping authorities alike.
This chapter, authored by Professor David Handelsman of the University of Sydney and published within the comprehensive Endotext reference resource, reviews the landscape of performance-enhancing hormone use in competitive sport. It covers the World Anti-Doping Agency framework, detection methodology, and the physiological basis for why certain hormones are exploited in specific sports.
The review identifies four pillars of athletic performance — skill, strength, endurance, and recovery — and maps each to specific doping strategies. Androgens (including natural steroids, synthetic steroidal compounds, and newer non-steroidal agents such as SARMs) are the most detected class of doping agents and are especially abused in power, combat, and collision sports due to their ability to increase muscle mass and strength. Erythropoiesis-stimulating agents and blood doping are the preferred tools for endurance athletes, as they increase oxygen-carrying capacity. Growth hormone and its secretagogues are used primarily to accelerate recovery from training and injury, although compelling evidence of ergogenic benefit remains elusive.
Hormones collectively account for approximately two-thirds of all anti-doping rule violations detected worldwide. While androgens remain relatively detectable, peptide hormones, growth hormone secretagogues, and autologous blood transfusions continue to evade reliable detection. Glucocorticoids, when used chronically, appear to impair muscle function; short-term high-dose use may blunt fatigue perception but is not prohibited. Thyroid hormone misuse is likely self-defeating, as hyperthyroidism promotes muscle wasting.
For clinicians, this review offers a practical framework for recognizing potential hormone doping in patients who are competitive athletes, understanding the physiological rationale behind each substance class, and appreciating the ongoing challenges in detection and regulation.
Key Findings
- Hormones account for approximately two-thirds of all anti-doping rule violations detected globally.
- Androgens — including SARMs — are the most widely detected doping agents, particularly in power and combat sports.
- Erythropoiesis-stimulating agents and blood doping are favored in endurance sports for boosting oxygen delivery.
- Growth hormone and secretagogues are used for recovery acceleration, but convincing ergogenic evidence is lacking.
- Chronic glucocorticoid and thyroid hormone use are likely counterproductive for athletic performance.
Methodology
This is a narrative review chapter published within Endotext, a continuously updated online endocrinology reference. It synthesizes existing literature and regulatory frameworks rather than presenting original experimental data. The most recent update is dated December 2025.
Study Limitations
This summary is based on the abstract and chapter overview only, as the full text is not openly accessible. As a narrative review, the chapter does not include meta-analytic statistics or systematic risk-of-bias assessment. Evidence quality for some agents (e.g., growth hormone as ergogenic) is noted within the abstract itself as lacking.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
